Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2012        Go!    
 
 
April 27, Thursday 2017 3:03 AM       

       HEADLINES: Oppn to boycott Minister Mani in assembly                                              Chennithala writes to Yechury demanding Mani’s ouster                                              Pinarayi comes down heavily on strike by Pembilai Orumai                                              Assembly adjourned after uproar over Mani issue                                              Is there need for deafening horns in govt vehicles, asks Human Rights Commission                                              EVM wave, not Modi wave: AAP on losing MCD polls                                              Terrorism will recoil on those who nurture it: India                                              Poll symbol case: AIADMK leader sent to 5-day police custody                                              Terrorism will recoil on those who nurture it: India                                              20 killed in clashes in DR Congo's Kasai region: UN                                              Jadhav case: India hands over mother's appeal to Pak                                              Brilliant Uthappa powers KKR to top of IPL 10                                              Kaumudi Facebook
       SCI&TECH Next Article: Water exists deeper in Earth than thought: study  
       New potent vaccine may spell end for HIV
 
         Posted on :16:07:12 Nov 28, 2016
   
A A
       Last edited on:16:07:12 Nov 28, 2016
         Tags: New potent vaccine, HIV
 
WASHINGTON: The largest and most advanced HIV vaccine trial has been launched in South Africa to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.
 
The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.
 
It aims to enroll 5,400 men and women, making it the where more than 1,000 people become infected with HIV every day.
 
"If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).
 
"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," said Fauci.
 
The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.
 
The experimental vaccine regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military HIV Research Programme and the Thai Ministry of Health.
 
The Thai trial delivered landmark results in 2009 when it found for the first time that a vaccine could prevent HIV infection, albeit modestly.
 
The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the HIV subtype that predominates in southern Africa, a region that includes the country of South Africa.
 
"The people of South Africa are making history by conducting and participating in the first HIV vaccine efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.
 
"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.
 
"If an HIV vaccine were found to work in South Africa, it may dramatically alter the course of the pandemic," she said. The experimental vaccine regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.
 
In the HVTN 702 study, the design, schedule and components of the RV144 vaccine regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.
 
HVTN 702 begins just months after interim results were reported for HVTN 100, its predecessor clinical trial, which found that the new vaccine regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144. 
A A
       SCI&TECH
Next Article: Water exists deeper in Earth than thought: study
 
 
SCI&TECH HEADLINES
Spacecraft flies between Saturn and rings in historic 1st  
Google targets 'fake news,' offensive search suggestions  
Offensive WhatsApp posts can land group admin in jail  
Facebook for 'everyone' and not just high end: Zuckerberg  
Google Earth re-invented for new era  
NASA images show how India looks from space at night  
Signs of life detected below world's deepest point  
'iPhones assembly in Bengaluru by Apple in less than a month'  
Five astronauts assigned to future ISS mission: NASA  
Trump plans to send humans to Mars  
First patient cured of rare blood disorder'  
Indian-American teen wins top science award worth USD 250,000  
'New extension may improve inflight WiFi'  
Frogs can see colour in extreme darkness: study  
NASA may put astronauts on deep space test flight  
Juno to remain in current orbit around Jupiter: NASA  
US man receives new face from donor  
Over 100 new potential planets spotted  
ISRO to launch record 104 satellites on Feb 15  
Now, video-makers can live stream on YouTube  
Music, drugs stimulate same part of brain: study  
Facebook adds tool for helping in times of crisis  
Moon may have formed from collision of tiny 'moonlets'  
China to set up world's highest altitude telescopes in Tibet  
NASA to launch two robotic probes to study early solar system  
 
Should Senkumar be reinstated as DGP, law and order?
yes
 
no
 
don't know
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy